Background: The cytokine profile plays an important role in treatment outcome of hepatitis C virus (HCV) infection, and probably modulates the immune response against HCV. The aim of this study was to evaluate which cytokines affect the response to interferon-a (IFN-a) and ribavirin therapy and how these cytokines change 72 weeks after starting anti-HCV therapy in HIV/HCV-coinfected patients.
Introduction
Coinfection with HIV and hepatitis C virus (HCV) is relatively common because both viruses share routes of transmission, 1 and progression of liver disease is accelerated in HIV/ HCV-coinfected patients. 2 Moreover, the use of highly active antiretroviral therapy (HAART) in HIV-infected patients has decreased the high levels of mortality and morbidity, but liver disease due to HCV infection has become a leading cause of morbidity and mortality in HIV-infected individuals. 3, 4 The current standard therapy in chronic hepatitis C (CHC) is pegylated interferon (peg-IFN)-a plus ribavirin, but HIV/HCV-coinfected patients have great difficulty achieving a sustained virological response (SVR). 5 The reason for non-responsiveness may be associated with the interaction between HIV and HCV infections, and the failure of the immune response, but this still remains unclear.
At least six distinct CD4+ T helper (Th) cell subsets have been reported as being capable of regulating the immune response of other cells and thus play a pivotal role in infections: (i) regulatory T cells (Tregs) secrete transforming growth factor (TGF)-b and interleukin (IL)-10, and play a critical role in maintaining selftolerance and regulation of immune response; 6 (ii) Th1 cells release interferon (IFN)-g and IL-2, and mediate immune responses against intracellular pathogens; 6 (iii) Th2 cells release IL-4, IL-5 and IL-13, and mediate host defence against extracellular parasites; 6 (iv) Th9 cells, first identified as a Th2 subpopulation, release IL-9 and IL-10, and mediate immune responses against parasitic helminth infections, and also drive the pathogenesis of allergy and asthma; 7 (v) Th17 cells release IL-17 and IL-22, mediate the inflammatory immune responses and are key regulators of homeostasis and epithelial barrier function; 8 and (vi) Th22 cells release tumour necrosis factor (TNF)-a and IL-22 (but not IFN-g, IL-4 or IL-17), and have protective/ regenerative effects on epithelial cells and liver. 8 However, although cytokines may come from a specific cell lineage, in many cases there are several types of lymphocytes that may produce the same cytokine. Thus TNF-a, IL-6, IL-9, IL-10, IL-17A and IL-22 may be released by Th1, Th2, Th9, Th17 or Th22 cells, limiting their own effector function. 6 -8 The cytokine profile plays an important role in treatment response to peg-IFN-a and ribavirin, and probably modulates the immune response against HCV.
9,10 Therefore, during anti-HCV therapy, IFN-a stimulates Th1 cells, but restrains Th2 response in HCV-monoinfected patients, suggesting that Th1 rather than Th2 cytokines may be important in eliminating the HCV infection. 9 -11 Besides, anti-HCV therapy is accompanied by a decreased secretion of the Th2 cytokines such as IL-4 and IL-10. 12 However, there is practically no data on plasma levels of IL-9, IL-17A and IL-22 in HIV/HCV-coinfected patients on anti-HCV therapy.
The aim of this study was to evaluate whether basal cytokine levels affect the response to IFN-a and ribavirin therapy and how these cytokines behave 72 weeks after starting anti-HCV therapy in HIV/HCV-coinfected patients. In order to achieve this objective, we chose cytometric bead array analysis to simultaneously identify 13 plasma cytokines associated with Th1, Th2, Th9, Th17 and Th22 responses.
Patients and methods

Patients
We carried out a retrospective follow-up study on 65 HIV/HCV-coinfected patients who started IFN plus ribavirin treatment at the Hospital General Universitario Gregorio Marañ ó n in Madrid (Spain). The starting criteria for HCV antiviral treatment were: (i) inclusion criteria: CHC, no clinical evidence of hepatic decompensation, detectable HCV RNA by PCR, negative for hepatitis B surface antigen, CD4+ T cell count .200 cells/mm 3 and stable HAART; and (ii) exclusion criteria: active opportunistic infections, active drug and/or alcohol addiction, and other concomitant diseases or conditions such as diabetes, nephropathies, autoimmune diseases, haemochromatosis, primary biliary cirrhosis, Wilson's disease, a1-antitrypsin deficiency and neoplasia. Furthermore, in the present study we included only patients with availability of a collected and frozen serum sample at baseline and 72 weeks after starting HCV therapy.
All work was conducted in accordance with the Declaration of Helsinki. All patients gave their written consent for the liver biopsy and the Institutional Ethics Committee approved the study.
Clinical and laboratory data
The following information was obtained from medical records: age, gender, risk category, weight, height, CDC clinical category, nadir CD4+ T cell count, antiretroviral therapy, grading and staging of liver biopsies according to Metavir score and HCV genotype. In addition, during HCV therapy a blood sample was taken from each patient to analyse complete blood counts, CD4+ T cells, plasma HIV viral load (HIV RNA) and plasma HCV viral load (HCV RNA), liver panel and basic metabolic panel. The degree of insulin resistance was estimated for each patient using the homeostatic model assessment (HOMA) method, which was obtained using the following formula: fasting plasma glucose (mmol/L) times fasting serum insulin (mU/L) divided by 22.5.
Treatment schedules and outcomes
Patients were treated for 48 weeks with IFN-a plus ribavirin. Three types of IFNs were used: standard non-peg-IFN-a-2b (Intron-A, ScheringPlough, Alcobendas, Madrid) at a dose of 3 MU three times per week, peg-IFN-a-2a (Pegasys, Roche Farma S.A., Madrid) at a dose of 180 mg/ week or peg-IFN-a-2b (Peg-Intron, Schering-Plough, Alcobendas, Madrid) at a dose of 1.5 mg/kg/week. All patients received ribavirin (Rebetol, Schering-Plough, Alcobendas, Madrid) at a dose of 800-1200 mg/day according to body weight. No patients had been previously treated with interferon and/or ribavirin. Anti-HCV therapy was ceased in patients with detectable HCV RNA at week 24 of treatment. An SVR was defined as an undetectable serum HCV RNA level (,50 IU/mL) up to 24 weeks after the end of treatment. Patients not fulfilling SVR criteria were considered as non-responders (NRs). 
Serum markers analysed
DNA genotyping
Genomic DNA from 55 of 65 patients was extracted from peripheral blood by using Qiagen columns (QIAamp DNA Blood Midi/Maxi, Qiagen, Hilden, Germany). The DNA was quantified by spectrophotometry (Tecan Infinite w 200 PRO Microplate Reader, Tecan Group Ltd, Mä nnedorf, Switzerland), diluted to a stock concentration of 50 ng/mL and stored at 2708C. In order to genotype four IL28B polymorphisms (rs12980275, rs8099917, rs7248668 and rs11881222), a minimum of 100 ng/mL DNA were sent to the Spanish National Genotyping Centre (CeGen; http://www.cegen.org/). Genotyping was performed using the GoldenGate w assay with VeraCode w Technology (Illumina Inc., San Diego, CA, USA).
Statistics
The statistical analysis was performed with the Statistical Package for the Social Sciences (SPSS) version 15.0 (SPSS Inc., Chicago, IL, USA) and STATA 10 (STATA, College Station, TX, USA). All P values were two-tailed. Statistical significance was defined as P,0.05. Categorical data and proportions were analysed using the x 2 test or Fisher's exact test. Mann-Whitney U test was used to compare data among independent groups (NR versus SVR) at baseline and 72 weeks after starting anti-HCV therapy. Wilcoxon test was used to compare data within related groups: HIV/HCV patient starting IFN-a plus ribavirin therapy (baseline) and the same patient after 72 weeks. We also performed univariate and multivariate logistic regression analyses to analyse the association among cytokines and SVR. In multiple logistic regression analysis, we included each cytokine (Enter algorithm) along with epidemiological and clinical characteristics (Stepwise algorithm, at each step, factors are considered for removal or entry: a P value for entry and exit of 0.10 and 0.20, respectively). Thus each logistic regression Plasma cytokines and anti-HCV therapy 1239 JAC was always adjusted for significant covariates associated with the outcome variable.
Receiver operating characteristic (ROC) curves were constructed in order to evaluate the predictive capability of virological response for anti-HCV therapy. For plasma cytokine levels, a cut-off near the 75th percentile was selected. This cut-off point separates 25% of patients with the highest values of plasma cytokine. Next, we calculated the sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) in order to evaluate the diagnostic performance. We also calculated the likelihood ratios (LRs), which describe how many times a patient with the target condition is more likely to have a particular test. Binary tests have two LRs, positive and negative (LR+ and LR2). We also calculated the diagnostic odds ratio (DOR), which expresses the strength of the association between the test result and disease: it is the ratio of the odds of a positive result in a person with the target condition compared with a person without that condition. A DOR or LR of 1 suggests the test provides no diagnostic evidence. Accuracy was defined as the percentage of correctly classified patients [(true positives+true negatives)/all patients].
Results
Patients
Our study included 65 HIV/HCV-coinfected patients whose characteristics at the time of starting anti-HCV therapy are shown in Table 1 .
Plasma cytokine levels at baseline during and after HCV antiviral therapy
At the beginning of anti-HCV therapy, NR patients had higher values of IL-6, IL-9, IL-10 and TNF-a than SVR patients (P,0.05); and SVR patients had higher plasma levels of IL-17A than NR patients, but only around the statistical significance (P ¼ 0.058) ( Table 2 ). During anti-HCV therapy, we observed a significant increase in plasma IL-1b levels in NR patients (P¼ 0.015) and a decrease in IL-10 levels in SVR patients (P ¼ 0.049) from baseline to week 72 (Table 2) . At week 72 after starting anti-HCV therapy, SVR patients had lower plasma values of IL-6, IL-9, IL-10, TNF-a, IL-13 and IL-22 than NR patients (P,0.05), and also IL-1b, but only near statistical significance (P ¼ 0.073) ( Table 2 ).
Association of baseline cytokines and SVR
We performed a logistic regression analysis in order to predict SVR from cytokines with significant differences at baseline (Table 3) . When we performed an unadjusted analysis, we found that patients with high plasma values of IL-6 and TNF-a had decreased odds to achieve SVR (P,0.05). High plasma levels of IL-9 were also associated with anti-HCV therapy failure, but only near statistical significance (P ¼0.070). When we performed an adjusted analysis, patients with high plasma values of IL-6 and IL-9 had decreased odds to achieve SVR (P,0.05).
Next, we performed ROC curve analysis for plasma IL-6 and IL-9 levels at the baseline, which were significantly associated with SVR in the previous adjusted regression analysis (Figure 1 ). Plasma levels of IL-6 and IL-9 showed a high predictive value for SVR failure [area under the ROC curve (AUC) 0.839 (95% CI 0.733-0.945) and AUC 0.769 (95% CI 0.653 -0.884), respectively].
We also identified an acceptable diagnostic performance of elevated IL-6 values (≥15 pg/mL) for predicting SVR in HIV/ HCV-coinfected patients on anti-HCV therapy (Table 4) . Regarding IL-9, the diagnostic performance of elevated IL-9 values (≥2 pg/ mL) was lower than for IL-6 for predicting SVR (Table 4) .
IL28B genotypes and level of cytokines associated with SVR
We analysed in 55 out 65 patients the influence of several IL28B polymorphisms (rs12980275, rs8099917, rs7248668 and rs11881222) on levels of IL-6 and IL-9, and virological response to anti-HCV therapy. All four single nucleotide polymorphisms (SNPs) fulfilled the minimum allele frequency (MAF) of .0.05 for all samples and were in Hardy-Weinberg equilibrium. rs8099917 and rs7248668 were in complete linkage disequilibrium, and therefore analysis was performed only once. As it was previously reported, 13 -15 we found that the favourable IL28B genotypes showed increased odds to remove HCV infection: AA at rs12980275 had an OR of 4.07 (95% CI 1.29 -12.58), TT at rs8099917 and GG at rs7248668 both had an OR of 11.57 (95% CI 2.26-59.07) and AA at rs11881222 had an OR of 3.55 (95% Guzmá n-Fulgencio et al. ). Moreover, we found that patients with favourable genotypes (AA at rs12980275, TT at rs8099917, GG at rs7248668and AA at rs11881222) showed reduced IL-9 plasma levels ( Table 5 ). The IL-6 plasma level was also lower in these patients, but the differences were not statistically significant (Table 5) . Finally, IL-6 and IL-9 continued to exhibit a significant association with SVR in a multivariate logistic regression analysis adjusted by several epidemiological and clinical factors and each one of the IL28B polymorphisms studied (Table 5) .
Discussion
There is very little information about plasma cytokines and virological response to IFN-a plus ribavirin in HIV/HCV-coinfected patients. In our study, NR patients had higher levels of IL-6, IL-9, IL-10 and TNF-a, while IL-17A levels were increased in SVR patients. However, only patients with high levels of IL-6 and IL-9 had decreased odds to achieve SVR. In addition, during anti-HCV therapy, IL-1b showed an increase in NR patients and IL-10 had a decrease in SVR patients, and after clearing HCV infection, low levels of Th2/Th9/Th22 cytokines (IL-6, IL-9, IL-10, IL-13, TNF-a and IL-22) were found in SVR patients. Since the second sample was extracted 24 weeks after completion of antiviral treatment, we hypothesize that this decrease in levels of Th2/Th9/Th22 cytokines might be due Values as ratio and 95% CI. mainly to the elimination of HCV rather than to a direct effect of IFN-a on the immune system. Th2 immune response has been associated with HCV infection persistence, 16 and is induced against HCV core protein. 17 In our study, non-response was associated with high levels of IL-6 and IL-10, which are considered Th2 cytokines, although they are also delivered by other Th cell lineages. 6 -8 Our data suggest that IL-6 and IL-10 might be crucial for controlling and clearing HCV infection. Genetic studies have shown that IL-6 and IL-10 gene polymorphisms affect the response to HCV antiviral treatment. 18, 19 Besides, IL-6 had the best predictive capability of anti-HCV therapy failure (ROC area .0.80). IL-6 is a cytokine induced by HCV proteins 20 associated with HCV infection persistence. 21, 22 Recently Funaoka et al. 21 reported that IL-6 up-regulates suppressors of cytokine signalling 3 (SOCS3), a potent inhibitor of the type I IFN pathway, producing IFN-a resistance by suppression of IFN signalling. Moreover, IL-10 is a cytokine that has a general suppressive function and inhibits proinflammatory responses from innate and adaptive immunity. 23 As well as our study, other authors have reported that increased peripheral levels of IL-10 are a negative prognostic marker of response to HCV treatment, 24 and anti-HCV therapy is accompanied by a decreased secretion of plasma IL-10 in HCV-monoinfected patients. 12 High levels of IL-10 in HCV infection have been suggested as being responsible for the poor antiviral cellular immune responses found in these patients. 25, 26 Moreover, since IL-10 also plays an immunosuppressive role in HIV infection, 26, 27 we believe that the elimination of HCV may help to improve HIV disease. Finally, IL-13, another Th2 cytokine, 6 showed reduced plasma values in SVR patients at week 72. Usually IL-13 is elevated in the plasma of HCV-infected patients with CHC, and it is correlated with the fibrosis stage. 28 In this case, the elimination of HCV infection may also promote a reduction of IL-13, protecting against liver injury.
Plasma cytokines and anti-HCV therapy
Th9 response has been associated with deficient production of Th1 cytokines, and this has been associated with severe disease in other infections such as tuberculosis, 29 H1N1 pandemic influenza virus 30 and respiratory syncytial virus (RSV) bronchiolitis. 31 Currently there are no published articles about plasma IL-9 in CHC patients coinfected with HIV. In our study, patients with high baseline levels of IL-9 had decreased odds of SVR, with an acceptable predictive capability of anti-HCV therapy failure (ROC area .0.75). IL-9 has also been demonstrated to participate in peripheral tolerance via Tregs. 32 Thus it is possible that high levels of IL-9 participate in peripheral tolerance to HCV and contribute to the failure of anti-HCV therapy.
TNF-a is a proinflammatory cytokine released by different types of cells, and it has been implicated in non-response to IFN in CHC. 33 In the present study, non-response was associated with high levels of TNF-a, but this association was lost after adjusting by clinical characteristics. TNF-a may influence the response to anti-HCV therapy via overexpression of SOCS3 in the liver of CHC patients. 34, 35 Th17 immunity participates in clearing pathogens during host defence reactions. 36 Thus Th17 cells are vital for clearance of viral infections with influenza virus 37 and hepatitis B virus. 38 Also, Th17 cells are implicated in host defence against HIV 39 and HCV. 40 In our study we found that SVR patients had high levels of IL-17A, but were not associated with SVR. IL-22 is mainly produced by Th17, Th22, gdT, natural killer (NK) and NK T cells, etc. 41 IL-22 appears to be an important factor in promoting hepatocyte survival and proliferation, 42 and provides protection to hepatocytes during acute liver inflammation. 43 Previous studies have reported that the expression of hepatic IL-22 is up-regulated in patients with viral hepatitis, 42, 44 and IL-22 does not inhibit HCV replication. 44 Our results showed that SVR patients had reduced levels of IL-22 at week 72 of the follow-up study. Thus IL-22 might play a compensatory role in protecting against hepatocellular damage, and the elimination of HCV might promote a reduction of IL-22, reflecting the stoppage of liver injury.
In addition, Th1 response seems to be the main factor that protects against HCV infection, 45 and may determine the outcome of antiviral therapy to CHC. 46, 47 However, in our study we did not find any association between baseline Th1 cytokines (IFN-g, IL-2 and IL-12) and SVR. It is possible that HIV infection, which also affects the Th1 response, 48 may be distorting the effect of Th1 cytokines on response to anti-HCV therapy.
Concerning host genetic factors, recently SNPs of the IL28B gene have been identified, which affect the effectiveness of anti-HCV therapy. 14, 49, 50 These polymorphisms have been implicated in the regulation of the expression of IFN-stimulated genes (ISGs), 51 which play critical roles in anti-HCV therapy response. 52 In our study we examined four IL28B genotypes (rs12980275, rs8099917, rs7248668 and rs11881222) and their association with IL-6 and IL-9 plasma levels in order to assess their predictive value in treatment outcome with IFN-a and ribavirin. As was previously reported, 13 -15 we found an association of these four SNPs with SVR. In addition, the favourable IL28B genotypes were associated with a low baseline of IL-9, but not IL-6, plasma levels. The association of the two cytokines (IL-6 and IL-9) with SVR remained significant after adjusting by several epidemiological and clinical factors, and each one of the IL28B genotypes studied. Therefore plasma values of IL-6 and IL-9 seem to be useful markers to predict the outcome of anti-HCV therapy in HIV/HCV-coinfected patients.
This study had several limitations that may impact our findings. First, the work presented here is a retrospective study with a small number of patients enrolled, thus it is inappropriate to draw conclusions on negative results. For example, we did not find any significant association among baseline levels of cytokines and parameters related to HCV infection, such as alanine transaminase (ALT), liver fibrosis, activity grade, HCV viral load, HCV genotype 1 and the HOMA method (data not shown). Thus these negative conclusions should be interpreted with caution and should be confirmed in further, larger longitudinal studies. Second, the study was focused on plasma biomarkers and does not provide data on Th cell function in stricto sensu. Third, and finally, levels of cytokines have been reported in HIV-infected patients depending on the CD4+ T cell count and HIV viral load, but our patients did not have severe immunodeficiency and HIV viral loads were not too high. Third, the levels of cytokine measured may be affected by factors related to storage of plasma, such as the stability of cytokines during long-time storage and upon freezing and thawing. 53 In our study we stored all samples below 2808C (the safest form of storage for plasmas of patients) for a variable period of time according to each patient, and with few exceptions, only 2-3 freezing/ thawing cycles of samples occurred.
In conclusion, high plasma levels of IL-6 and IL-9 had a high predictive value for SVR failure. Furthermore, clearing of HCV infection was associated with low inflammatory and Th2/Th9/ Th22 cytokines levels.
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